Research programme: stem cell-based therapeutics - Pluristem Therapeutics

Drug Profile

Research programme: stem cell-based therapeutics - Pluristem Therapeutics

Alternative Names: Placenta expanded mesenchymal cells; Placental-derived mesenchymal stem cells; PLX-BMP; PLX-BMT; PLX-I; PLX-IBD; PLX-Immune; PLX-MS; PLX-ORTHO; PLX-PAH; PLX-STROKE

Latest Information Update: 14 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pluristem Life Systems
  • Developer Berlin-Brandenburg Center for Regenerative Therapies; Hebrew University of Jerusalem; New York University School of Medicine; Pluristem Therapeutics; Texas A&M University; United Therapeutics Corporation
  • Class Analgesics; Anti-inflammatories; Antineoplastics; Cardiovascular therapies; Neuroprotectants; Stem cell therapies
  • Mechanism of Action Cell replacements; Cytokine stimulants; Dopaminergic cell replacements; Stem cell stimulants; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer; Multiple sclerosis; Musculoskeletal disorders; Myocardial infarction; Preeclampsia; Pulmonary arterial hypertension; Pulmonary fibrosis; Stroke
  • No development reported Diabetic foot; Haematological malignancies; Heart failure; Inflammatory bowel diseases; Neuropathic pain; Pain; Parkinson's disease

Most Recent Events

  • 14 Feb 2018 Preclinical development is underway in Preeclampsia, Musculoskeletal disorders, Myocardial infarction, Pulmonary fibrosis, Multiple sclerosis and Pulmonary hypertension (Pluristem Therapeutics website, February 2018)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Heart-failure in Europe (IM)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Multiple-sclerosis in Germany (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top